Research Article 
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Michael H. Davidson, Kevin C. Maki, Harold Bays, Roderick Carter and Christie M. Ballantyne
Journal of Clinical Lipidology, 2009, 3(5), 332-340. DOI: 10.1016/j.jacl.2009.08.001
Abstract
Background
Prescription omega-3-acid ethyl esters (P-OM3) often are used for hypertriglyceridemic patients receiving statin therapy who have residual increases in atherogenic lipoprotein lipid levels. To date, limited information has been published regarding the effects of omega-3 fatty acid consumption on lipoprotein particle concentrations.
Objective
We evaluated the effects of adding P-OM3 4 g/d to an ongoing regimen of simvastatin 40 mg/d on lipoprotein particles (P) in subjects with hypertriglyceridemia.
Methods
Data were analyzed from the multicenter, randomized, double-blind, placebo-controlled Combination of Prescription Omega-3s with Simvastatin (COMBOS) study. After an 8-week simvastatin lead-in, 254 subjects received P-OM3 (n=122) or placebo (n=132) for an additional 8 weeks. Nuclear magnetic resonance spectroscopy was used to assess lipoprotein concentrations and sizes. Remnant-like particle cholesterol, apolipoprotein (Apo) CIII, Apo AI, and lipoprotein-associated phospholipase A2 (Lp-PLA2) levels also were measured.
Results
Compared with placebo, P-OM3 reduced mean very-low-density lipoprotein (VLDL-P) size and increased low-density lipoprotein particle (LDL-P) size (P < .006 for both) without altering high-density lipoprotein particle (HDL-P) size. P-OM3 did not significantly change total VLDL-P or LDL-P concentrations relative to placebo, but large VLDL-P and intermediate-density lipoprotein particle (IDL-P) concentrations were lowered (P < .01 for both), and the large LDL-P concentration was increased (P < .0001). HDL-P concentration was reduced (P < .0001) as the result of a decrease in medium HDL-P. Remnant-like particle cholesterol, Apo CIII, and Lp-PLA2 concentrations were reduced compared with placebo (all P < .003).
Conclusions
P-OM3 induces changes in sizes, concentrations, and compositions of lipoproteins that may have relevance for the atherothrombotic process.
ASCI-ID: 2746-113
Similar Articles
High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis
Journal of Clinical Lipidology, 2008, 2(1), 4-11. DOI: 10.1016/j.jacl.2007.11.002
Optimal management of lipids in diabetes and metabolic syndromeJournal of Clinical Lipidology, 2008, 2(5), 335-342. DOI: 10.1016/j.jacl.2008.08.444
Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME StudyJournal of Clinical Lipidology, 2009, 3(2), 109-118. DOI: 10.1016/j.jacl.2009.02.009
High-density lipoproteins: Marker of cardiovascular risk and therapeutic targetJournal of Clinical Lipidology, 2010, 4(5), 359-364. DOI: 10.1016/j.jacl.2010.08.002
Myeloperoxidase, inflammation, and dysfunctional high-density lipoproteinJournal of Clinical Lipidology, 2010, 4(5), 382-388. DOI: 10.1016/j.jacl.2010.08.007
High-density lipoprotein subclasses and their relationship to cardiovascular diseaseJournal of Clinical Lipidology, 2012, 6(6), 496-523. DOI: 10.1016/j.jacl.2012.03.001
A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier diseaseJournal of Clinical Lipidology, 2013, 7(1), 82-87. DOI: 10.1016/j.jacl.2012.09.004
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid AssociationJournal of Clinical Lipidology, 2013, 7(4), 304-383. DOI: 10.1016/j.jacl.2013.04.001
Effects of bariatric surgery on HDL structure and functionality: results from a prospective trialJournal of Clinical Lipidology, 2014, 8(4), 408-417. DOI: 10.1016/j.jacl.2014.05.001
A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case reportJournal of Clinical Lipidology, 2014, 8(4), 455-459. DOI: 10.1016/j.jacl.2014.05.003
Prevalence of dyslipidemia and associated risk factors in Turkish adultsJournal of Clinical Lipidology, 2014, 8(2), 206-216. DOI: 10.1016/j.jacl.2013.12.011
Association between the FABP2 Ala54Thr, PPARα Leu162/Val, and PPARα intron7 polymorphisms and blood lipids ApoB and ApoCIII in hypertriglyceridemic subjects in TehranJournal of Clinical Lipidology, 2009, 3(3), 187-194. DOI: 10.1016/j.jacl.2009.04.001
Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation inductionJournal of Clinical Lipidology, 2008, 2(1), 63-66. DOI: 10.1016/j.jacl.2007.11.001
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) studyJournal of Clinical Lipidology, 2008, 2(2), 79-90. DOI: 10.1016/j.jacl.2008.02.004
Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaJournal of Clinical Lipidology, 2009, 3(5), 341-344. DOI: 10.1016/j.jacl.2009.09.003
Severe hypertriglyceridemiaJournal of Clinical Lipidology, 2012, 6(5), 397-408. DOI: 10.1016/j.jacl.2012.08.002
The interaction of familial and secondary causes of hypertriglyceridemia: Role in pancreatitisJournal of Clinical Lipidology, 2012, 6(5), 409-412. DOI: 10.1016/j.jacl.2012.06.005
Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidenceJournal of Clinical Lipidology, 2012, 6(5), 413-426. DOI: 10.1016/j.jacl.2012.04.003
Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoproteinJournal of Clinical Lipidology, 2012, 6(5), 427-433. DOI: 10.1016/j.jacl.2012.04.081
Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemiaJournal of Clinical Lipidology, 2012, 6(5), 443-449. DOI: 10.1016/j.jacl.2012.03.002
Pseudohypertriglyceridemia: Two cases of probable glycerol kinase deficiencyJournal of Clinical Lipidology, 2012, 6(5), 469-473. DOI: 10.1016/j.jacl.2012.02.001
Plasma exchange for severe hypertriglyceridemia-induced pancreatitis in an orthotopic heart transplant recipientJournal of Clinical Lipidology, 2012, 6(5), 474-476. DOI: 10.1016/j.jacl.2012.01.003
Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)Journal of Clinical Lipidology, 2012, 6(6), 565-572. DOI: 10.1016/j.jacl.2012.07.001
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) studyJournal of Clinical Lipidology, 2012, 6(6), 573-584. DOI: 10.1016/j.jacl.2012.01.002
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) studyJournal of Clinical Lipidology, 2013, 7(3), 199-207. DOI: 10.1016/j.jacl.2013.01.006
Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variationJournal of Clinical Lipidology, 2013, 7(6), 566-572. DOI: 10.1016/j.jacl.2013.09.003
Resequencing the untranslated regions of the lipoprotein lipase (LPL) gene reveals that variants in microRNA target sequences are associated with triglyceride levelsJournal of Clinical Lipidology, 2013, 7(6), 610-614. DOI: 10.1016/j.jacl.2013.09.006
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) studyJournal of Clinical Lipidology, 2013, 7(6), 615-625. DOI: 10.1016/j.jacl.2013.09.002
Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemiaJournal of Clinical Lipidology, 2013, 7(6), 671-674. DOI: 10.1016/j.jacl.2013.05.003
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trialJournal of Clinical Lipidology, 2014, 8(1), 94-106. DOI: 10.1016/j.jacl.2013.10.003
Combined dyslipidemia in obese children: Response to a focused lifestyle approachJournal of Clinical Lipidology, 2014, 8(2), 181-186. DOI: 10.1016/j.jacl.2014.01.003
Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: A matched cohort studyJournal of Clinical Lipidology, 2014, 8(3), 279-286. DOI: 10.1016/j.jacl.2014.02.002
Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patientsJournal of Clinical Lipidology, 2009, 3(3), 195-200. DOI: 10.1016/j.jacl.2009.04.055
Elevated atherogenic lipoproteins in childhood: Risk, prevention, and treatmentJournal of Clinical Lipidology, 2008, 2(3), 138-146. DOI: 10.1016/j.jacl.2008.04.006
Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitusJournal of Clinical Lipidology, 2012, 6(4), 318-324. DOI: 10.1016/j.jacl.2012.05.005
Compliance with the Adult Treatment Panel III guidelines for hyperlipidemia in a resident-run ambulatory clinic: A retrospective data analysisJournal of Clinical Lipidology, 2013, 7(1), 43-47. DOI: 10.1016/j.jacl.2012.06.004
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid AssociationJournal of Clinical Lipidology, 2013, 7(4), 304-383. DOI: 10.1016/j.jacl.2013.04.001
Prevalence of dyslipidemia and associated risk factors in Turkish adultsJournal of Clinical Lipidology, 2014, 8(2), 206-216. DOI: 10.1016/j.jacl.2013.12.011
Effects of Niacin Extended-Release/Simvastatin Versus Simvastatin Monotherapy on Plasma Lipids in Patients with or without High Baseline TriglyceridesJournal of Clinical Lipidology, 2008, 2(3), 220-221. DOI: 10.1016/j.jacl.2008.04.034
The Combination of Niacin Extended-Release with Simvastatin Improves Lipid Levels in Treatment-Naive PatientsJournal of Clinical Lipidology, 2008, 2(3), 221-222. DOI: 10.1016/j.jacl.2008.04.036
Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetesJournal of Clinical Lipidology, 2008, 2(1), 19-24. DOI: 10.1016/j.jacl.2007.12.004
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinJournal of Clinical Lipidology, 2008, 2(6), 436-446. DOI: 10.1016/j.jacl.2008.10.003
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patientsJournal of Clinical Lipidology, 2010, 4(4), 272-278. DOI: 10.1016/j.jacl.2010.05.002
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patientsJournal of Clinical Lipidology, 2011, 5(3), 179-187. DOI: 10.1016/j.jacl.2011.02.009
Appropriateness of Simvastatin Prescribing in a Community PracticeJournal of Clinical Lipidology, 2012, 6(3), 263-264. DOI: 10.1016/j.jacl.2012.04.029
A randomized trial of coenzyme Q10 in patients with statin myopathy: Rationale and study designJournal of Clinical Lipidology, 2013, 7(3), 187-193. DOI: 10.1016/j.jacl.2013.02.002